Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients
Authors:
Open Access
- 28 September 2007
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (10) , 3226-3235
Abstract
Objective: To assess whether disease activity levels at treatment initiation or during the first 3 months of therapy predict disease activity at 1 year after treatment initiation.Methods: Pooled patient data from early rheumatoid arthritis (RA) clinical trials (n = 1,342) of methotrexate (MTX), tumor necrosis factor (TNF) inhibitor monotherapy (adalimumab and etanercept), and the combination of the two (adalimumab or infliximab plus MTX) were used for the primary analyses. Pooled data from clinical trials of MTX and of TNF inhibitor plus MTX in late RA (n = 712) were used for validation of the results. Disease activity was primarily assessed using the Simplified Disease Activity Index (SDAI); in addition, we calculated the Disease Activity Score 28‐joint assessment (DAS28) and the Clinical Disease Activity Index (CDAI). Associations of disease activity measures at baseline and at 1, 2, 3, and 6 months with disease activity values or disease activity states at 1 year were performed using Spearman's rank correlation, analysis of variance, and diagnostic testing procedures, including receiver operating characteristic (ROC) curve analyses, and probit analysis.Results: Correlations with SDAI values at end point were significant (P< 0.0001) at baseline, and increased to r = ∼0.6 at 3 months. The area under the ROC curve indicated a high diagnostic test yield with respect to the 1‐year outcome (area under the ROC curve ∼0.8). At all time points, including baseline, the group of patients who achieved remission at 1 year had lower average SDAI values than did those whose disease activity was high at 1 year. The groups achieving low or moderate disease activities at 1 year had SDAI values lying between. Baseline disease activity was less associated with disease activity at the end point for treatment with TNF inhibitor plus MTX, indicating its effectiveness over a broader range of baseline disease activity, but the association with end point disease activity was similar to that in the MTX treatment group at 1 month after treatment initiation. The data were similar when scores on the DAS28 and CDAI were used and were fully validated in the independent cohort of patients with late RA.Conclusion: The level of disease activity at baseline and especially during the first 3 months of treatment is significantly related to the level of disease activity at 1 year. Patients who reach a moderate or low disease activity status after 3–6 months of therapy may require switching to alternative therapies. Our findings indicate that intensive and dynamic treatment strategies that include a closer look at disease activity at 3 months in patients with early and late RA is warranted.Keywords
This publication has 42 references indexed in Scilit:
- Assessing remission in clinical practiceRheumatology, 2007
- A proposed revision to the ACR20: The hybrid measure of American College of Rheumatology responseArthritis Care & Research, 2007
- The cost of dichotomising continuous variablesBMJ, 2006
- Challenges of predicting treatment response in patients with rheumatoid arthritisNature Clinical Practice Rheumatology, 2005
- Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two‐year randomized trialArthritis & Rheumatism, 2005
- Rheumatoid arthritis therapy after tumor necrosis factor and interleukin‐1 blockadeArthritis & Rheumatism, 2003
- Rheumatoid arthritis in 2003: where are we now with treatment?Annals of the Rheumatic Diseases, 2003
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995